Gene · 7150
Papers4,103
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 4,103
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Dysregulation of Amino Acid Transporters in a Rat Model of TLR7-Mediated Maternal Immune Activation. | Pharmaceutics | 2023 | 37514044 | PubTator, text mining | PubMed |
| Lactate Can Modulate the Antineoplastic Effects of Doxorubicin and Relieve the Drug's Oxidative Damage on Cardiomyocytes. | Cancers (Basel) | 2023 | 37509389 | PubTator, text mining | PubMed |
| The Multiple Faces of the MRN Complex: Roles in Medulloblastoma and Beyond. | Cancers (Basel) | 2023 | 37509263 | PubTator, text mining | PubMed |
| Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis. | RMD Open | 2023 | 37507206 | PubTator, text mining | PubMed |
| TXLNA enhances TBK1 phosphorylation by suppressing PPM1B recruitment. | Biochim Biophys Acta Mol Cell Res | 2023 | 37506885 | PubTator, text mining | PubMed |
| ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer. | EMBO Mol Med | 2023 | 37491889 | PubTator, text mining | PubMed |
| In Vitro Antiproliferative Effects and Phytochemical Characterization of Carissa edulis ((Forssk) Vahl) and Pappea capensis (Eckyl and Zeyh) Extracts. | J Evid Based Integr Med | 2023 | 37489007 | PubTator, text mining | PubMed |
| Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. | Nat Med | 2023 | 37488289 | PubTator, text mining | PubMed |
| Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1. | Nat Commun | 2023 | 37474525 | PubTator, text mining | PubMed |
Identification of N-(3-(methyl(3-(orotic amido)propyl)amino)propyl) oleanolamide as a novel topoisomerase I catalytic inhibitor by rational design, molecular dynamics simulation, and biological evaluation. | Bioorg Chem | 2023 | 37473480 | PubTator, text mining | PubMed |
| SiteFerret: Beyond Simple Pocket Identification in Proteins. | J Chem Theory Comput | 2023 | 37470784 | PubTator, text mining | PubMed |
| The central role of DNA damage in immunosenescence. | Front Aging | 2023 | 37465119 | PubTator, text mining | PubMed |
| Clinical characteristics of hypersensitivity pneumonitis: non-fibrotic and fibrotic subtypes. | Chin Med J (Engl) | 2023 | 37464421 | PubTator, text mining | PubMed |
| Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia. | Reprod Biol Endocrinol | 2023 | 37464405 | PubTator, text mining | PubMed |
| A dual-function SNF2 protein drives chromatid resolution and nascent transcripts removal in mitosis. | EMBO Rep | 2023 | 37462213 | PubTator, text mining | PubMed |
| Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. | J Exp Clin Cancer Res | 2023 | 37460927 | PubTator, text mining | PubMed |
| Integrated multiomic analysis and high-throughput screening reveal potential gene targets and synergetic drug combinations for osteosarcoma therapy. | MedComm (2020) | 2023 | 37457661 | PubTator, text mining | PubMed |
| Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. | Cancer Drug Resist | 2023 | 37457133 | PubTator, text mining | PubMed |
| Protective effects of hsa_circ_0072568 on interleukin‑1β‑stimulated human chondrocytes are mediated via the miR‑382‑5p/TOP1 axis. | Exp Ther Med | 2023 | 37456162 | PubTator, text mining | PubMed |
| Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade. | Int J Mol Sci | 2023 | 37446144 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7150/papers?page=27